Search

Your search keyword '"Timon, G."' showing total 169 results
Start Over Author "Timon, G."
169 results on '"Timon, G."'

2. DEPFET active pixel detectors for a future linear $e^+e^-$ collider

Author

Alonso, O., Casanova, R., Dieguez, A., Dingfelder, J., Hemperek, T., Kleinohl, T. Kishishita amd T., Koch, M., Krueger, H., Lemarenko, M., Luetticke, F., Marinas, C., Schnell, M., Wermes, N., Campbell, A., Ferber, T., Kleinwort, C., Niebuhr, C., Soloviev, Y., Steder, M., Volkenborn, R., Yaschenko, S., Fischer, P., Kreidl, C., Peric, I., Knopf, J., Ritzert, M., Curras, E., Lopez-Virto, A., Moya, D., Vila, I., Boronat, M., Esperante, D., Fuster, J., Garcia, I. Garcia, Lacasta, C., Oyanguren, A., Ruiz, P., Timon, G., Vos, M., Gessler, T., Kuehn, W., Lange, S., Muenchow, D., Spruck, B., Frey, A., Geisler, C., Schwenker, B., Wilk, F., Barvich, T., Heck, M., Heindl, S., Lutz, O., Mueller, Th., Pulvermacher, C., Simonis, H. J., Weiler, T., Krausser, T., Lipsky, O., Rummel, S., Schieck, J., Schlueter, T., Ackermann, K., Andricek, L., Chekelian, V., Chobanova, V., Dalseno, J., Kiesling, C., Koffmane, C., Gioi, L. Li, Moll, A., Moser, H. G., Mueller, F., Nedelkovska, E., Ninkovic, J., Petrovics, S., Prothmann, K., Richter, R., Ritter, A., Ritter, M., Simon, F., Vanhoefer, P., Wassatsch, A., Dolezal, Z., Drasal, Z., Kodys, P., Kvasnicka, P., and Scheirich, J.

Subjects
Physics - Instrumentation and Detectors, High Energy Physics - Experiment
Abstract

The DEPFET collaboration develops highly granular, ultra-transparent active pixel detectors for high-performance vertex reconstruction at future collider experiments. The characterization of detector prototypes has proven that the key principle, the integration of a first amplification stage in a detector-grade sensor material, can provide a comfortable signal to noise ratio of over 40 for a sensor thickness of 50-75 $\mathrm{\mathbf{\mu m}}$. ASICs have been designed and produced to operate a DEPFET pixel detector with the required read-out speed. A complete detector concept is being developed, including solutions for mechanical support, cooling and services. In this paper the status of DEPFET R & D project is reviewed in the light of the requirements of the vertex detector at a future linear $\mathbf{e^+ e^-}$ collider., Comment: 10 pages

Published
2012
Full Text
View/download PDF

3. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: Freedom from biochemical, radiological progression free survival and freedom from following treatment approaches within a randomized phase II trial (ARTO – NCT03449719)

Author

Francolini, G., primary, Detti, B., additional, Di Cataldo, V., additional, Caini, S., additional, Bruni, A., additional, Ingrosso, G., additional, D’angelillo, R.M., additional, Alitto, A.R., additional, Augugliaro, M., additional, Triggiani, L., additional, Parisi, S., additional, Facchini, G., additional, Banini, M., additional, Simontacchi, G., additional, Desideri, I., additional, Meattini, I., additional, Frosini, G., additional, Burchini, L., additional, Marvaso, G., additional, Alongi, F., additional, Arcidiacono, F., additional, Lancia, A., additional, Genovesi, D., additional, Franzese, C., additional, Timon, G., additional, Tagliagambe, A., additional, and Livi, L., additional

Published
2023
Full Text
View/download PDF

4. Attitudes, practices and perspectives on imaging strategies in prostate cancer: a national cross-sectional survey involving expert radiation oncologists on behalf of AIRO (Italian association of radiotherapy and clinical oncology) GU group

Author

Lucchini, R, Francolini, G, Matrone, F, Timon, G, Franzese, C, Marvaso, G, Borghetti, P, Nicosia, L, Trodella, L, Vinciguerra, A, Jereczek-Fossa, B, Arcangeli, S, Lucchini R., Francolini G., Matrone F., Timon G., Franzese C., Marvaso G., Borghetti P., Nicosia L., Trodella L. E., Vinciguerra A., Jereczek-Fossa B. A., Arcangeli S., Lucchini, R, Francolini, G, Matrone, F, Timon, G, Franzese, C, Marvaso, G, Borghetti, P, Nicosia, L, Trodella, L, Vinciguerra, A, Jereczek-Fossa, B, Arcangeli, S, Lucchini R., Francolini G., Matrone F., Timon G., Franzese C., Marvaso G., Borghetti P., Nicosia L., Trodella L. E., Vinciguerra A., Jereczek-Fossa B. A., and Arcangeli S.

Abstract

Although high sensitive imaging modalities such as MRI and PSMA PET/CT are becoming available for prostate cancer (PCa), the clinical benefit of an earlier detection of subclinical disease remains yet undetermined. Given these uncertainties, univocal recommendations are often lacking. The present survey was therefore developed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) to collect the opinion of expert radiation oncologists and delineate a representation of current clinical practice in our country. A nationwide cross-sectional survey was conducted in Italy by administering an anonymous questionnaire to experienced radiation oncologists, representative of the genitourinary (GU) tumor board at their Institution, using the cloud-based platform SurveyMonkey®. For each question, a consensus was achieved when ≥ 75% of the responders agreed on the same response. Thirty nine AIRO members from different Italian centers who were deemed experts in GU field accessed the proposed survey and completed all sections. Explored topics included staging of organ-confined disease, management of biochemical and local recurrence, imaging in the metastatic setting, imaging following metastasis-directed therapy (MDT), and future considerations. Response rate for single item of the questionnaire ranged between 51.2% and 100%. Expert GU AIRO members agree that advanced molecular and functional imaging are expanding their role in local and distant staging of PCa, as well as in the oncologic management and in the assessment of treatment response. However, many controversial issues still exist on the best timing for a diagnostic evaluation and the most appropriate imaging to aim at this purpose.

Published
2022

5. PO-1491 Profiling PCa patients with BCR in the era of early imaging detection: an AIRO-URO group study

Author

Marvaso, G., primary, Matrone, F., additional, Magli, A., additional, Francolini, G., additional, Villa, R., additional, Mastroleo, F., additional, Franzese, C., additional, Nicosia, L., additional, Pasqualetti, F., additional, Trodella, L.E., additional, Vinciguerra, A., additional, Barra, S., additional, Timon, G., additional, Augugliaro, M., additional, Zaffaroni, M., additional, Corrao, G., additional, Vincin, M.G., additional, Scorsetti, M., additional, Jereczek-Fossa, B.A., additional, Arcangeli, S., additional, and Triggiani, L., additional

Published
2023
Full Text
View/download PDF

6. PO-1494 Process mining in PCa Salvage RT patients care path: an AIRO-URO group preliminary analysis

Author

Mastroleo, F., primary, Marvaso, G, additional, Villa, R., additional, Zaffaroni, M., additional, Corrao, G., additional, Vincini, M.G., additional, Matrone, F., additional, Magli, A., additional, Francolini, G., additional, Franzese, C., additional, Nicosia, L., additional, Pasqualetti, F., additional, Trodella, L., additional, Vinciguerra, A., additional, Barra, S., additional, Timon, G., additional, Augugliaro, M., additional, Scorsetti, M., additional, Jereczek-Fossa, B.A., additional, Arcangeli, S., additional, and Triggiani, L., additional

Published
2023
Full Text
View/download PDF

7. Radiotherapy role in non-seminomatous germ cell tumors, radiobiological and technical issues of an unexplored scenario

Author

Francolini, G, Trodella, L, Marvaso, G, Matrone, F, Nicosia, L, Timon, G, Ognibene, L, Vinciguerra, A, Franzese, C, Borghetti, P, Arcangeli, S, Francolini G., Trodella L. E., Marvaso G., Matrone F., Nicosia L., Timon G., Ognibene L., Vinciguerra A., Franzese C., Borghetti P., Arcangeli S., Francolini, G, Trodella, L, Marvaso, G, Matrone, F, Nicosia, L, Timon, G, Ognibene, L, Vinciguerra, A, Franzese, C, Borghetti, P, Arcangeli, S, Francolini G., Trodella L. E., Marvaso G., Matrone F., Nicosia L., Timon G., Ognibene L., Vinciguerra A., Franzese C., Borghetti P., and Arcangeli S.

Abstract

Historically, non-seminomatous germ cell tumor (NSGCT) has been considered a radio-resistant disease, excluding radiotherapy (RT) from curative strategies. However, case series exploring the use of radiation treatment in this setting are often outdated, and prospective ongoing studies testing new radiotherapeutic approaches in NSGCT are lacking. Considering that tremendous advances in radiotherapy technology have enabled improved precision in RT delivery as well as dose escalation while decreasing treatment-related morbidity, we overviewed the currently available literature to explore the radiobiological basis, the technical issues, and potential strategies for implementation of RT in the management of this clinical entity. The purpose of the present overview is to provide insight for future research in this unexplored scenario. In summary, the biological rationale for RT use and potential implementation with systemic therapies exist, especially considering the advantage of new technologies, which were unavailable in the era of early literature reports. The NSGCT radioresistance paradigm could be based only on the fact that effective treatment schedules were simply undeliverable with older RT techniques due to toxicity issues, but the availability of actual techniques may prompt further exploration to offer treatment alternatives to these patients. Ongoing trials on this issue are lacking, but potential areas of research are platinum-refractory disease and consolidation therapy for residual masses after PST.

Published
2021

8. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group

Author

Franzese, C, Marvaso, G, Francolini, G, Borghetti, P, Trodella, L, Sepulcri, M, Matrone, F, Nicosia, L, Timon, G, Ognibene, L, Vinciguerra, A, Alongi, F, Bortolus, R, Corti, L, Ramella, S, Magrini, S, Livi, L, Jereczek-Fossa, B, Scorsetti, M, Arcangeli, S, Franzese C., Marvaso G., Francolini G., Borghetti P., Trodella L. E., Sepulcri M., Matrone F., Nicosia L., Timon G., Ognibene L., Vinciguerra A., Alongi F., Bortolus R., Corti L., Ramella S., Magrini S. M., Livi L., Jereczek-Fossa B. A., Scorsetti M., Arcangeli S., Franzese, C, Marvaso, G, Francolini, G, Borghetti, P, Trodella, L, Sepulcri, M, Matrone, F, Nicosia, L, Timon, G, Ognibene, L, Vinciguerra, A, Alongi, F, Bortolus, R, Corti, L, Ramella, S, Magrini, S, Livi, L, Jereczek-Fossa, B, Scorsetti, M, Arcangeli, S, Franzese C., Marvaso G., Francolini G., Borghetti P., Trodella L. E., Sepulcri M., Matrone F., Nicosia L., Timon G., Ognibene L., Vinciguerra A., Alongi F., Bortolus R., Corti L., Ramella S., Magrini S. M., Livi L., Jereczek-Fossa B. A., Scorsetti M., and Arcangeli S.

Abstract

Although systemic therapy represents the standard of care for polymetastatic kidney cancer, stereotactic body radiation therapy (SBRT) may play a relevant role in the oligometastatic setting. We conducted a multicenter study including oligometastatic kidney cancer treated with SBRT. We retrospectively analyzed 207 patients who underwent 245 SBRT treatments on 385 lesions, including 165 (42.9%) oligorecurrent (OR) and 220 (57.1%) oligoprogressive (OP) lesions. Most common sites were lung (30.9%) for OR group, and bone (32.7%) for OP group. Among 78 (31.8%) patients receiving concomitant systemic therapy, sunitinib (61.5%) and pazopanib (15.4%) were the most common for OR patients, while sunitinib (49.2%) and nivolumab (20.0%) for OP patients. End points were local control (LC), progression free survival (PFS), overall survival (OS), time to next systemic therapy (TTNS) and toxicity. Median follow-up was 18.6 months. 1, 2 and 3-year LC rates were 89.4%, 80.1% and 76.6% in OR patients, and 82.7%, 76.9% and 64.3% in those with OP, respectively. LC for OP group was influenced by clear cell histology (p = 0.000), total number of lesions (p = 0.004), systemic therapy during SBRT (p = 0.012), and SBRT dose (p = 0.012). Median PFS was 37.9 months. 1, 2- and 3-year OS was 92.7%, 86.4% and 81.8%, respectively. Median TTNS was 15.8 months for OR patients, and 13.9 months for OP patients. No grade 3 or higher toxicities were reported for both groups. SBRT may be considered an effective safe option in the multidisciplinary management of both OR and OP metastases from kidney cancer.

Published
2021

9. Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point—a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)

Author

Francolini, G, Timon, G, Matrone, F, Marvaso, G, Nicosia, L, Ognibene, L, Vinciguerra, A, Trodella, L, Franzese, C, Borghetti, P, Jereczek-Fossa, B, Arcangeli, S, Francolini G., Timon G., Matrone F., Marvaso G., Nicosia L., Ognibene L., Vinciguerra A., Trodella L. E., Franzese C., Borghetti P., Jereczek-Fossa B. A., Arcangeli S., Francolini, G, Timon, G, Matrone, F, Marvaso, G, Nicosia, L, Ognibene, L, Vinciguerra, A, Trodella, L, Franzese, C, Borghetti, P, Jereczek-Fossa, B, Arcangeli, S, Francolini G., Timon G., Matrone F., Marvaso G., Nicosia L., Ognibene L., Vinciguerra A., Trodella L. E., Franzese C., Borghetti P., Jereczek-Fossa B. A., and Arcangeli S.

Abstract

Objectives: Postoperative prostate cancer patients are a heterogeneous population, and many prognostic factors (e.g., local staging, PSA kinetics, margin status, histopathological features) may influence their clinical management. In this complex scenario, univocal recommendations are often lacking. For these reasons, the present survey was developed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) to collect the opinion of Italian radiation oncologists and delineate a representation of current clinical practice in our country. Methods: A questionnaire was administered online to AIRO (Italian Association of Radiotherapy and Clinical Oncology) members registered in 2020 with a clinical interest in uro-oncological disease. Results: Sixty-one per cent of AIRO members answered the proposed survey. Explored topics included career and expertise, indications to adjuvant RT, additional imaging in biochemical recurrence setting, use of salvage radiotherapy (SRT), management of clinically evident locoregional recurrence and future considerations. Conclusions: Overall, good level of agreement was found between participants for most of the topics. Most debated issues regarded, as expected, implementation of new imaging methods in this setting. Notably, trend in favour of early SRT vs. immediate adjuvant RT was underlined, and preference for global evaluation rather than isolated risk factors for RT indications was noticed.

Published
2021

10. The role of palliative radiotherapy in the management of elderly and frail patients with advanced bladder cancer: A survey by the AIRO uro-group

Author

Marvaso, G, Nicosia, L, Vinciguerra, A, Borghetti, P, Trodella, L, Francolini, G, Timon, G, Matrone, F, Ognibene, L, Franzese, C, Jereczek-Fossa, B, Arcangeli, S, Marvaso G., Nicosia L., Vinciguerra A., Borghetti P., Trodella L. E., Francolini G., Timon G., Matrone F., Ognibene L., Franzese C., Jereczek-Fossa B. A., Arcangeli S., Marvaso, G, Nicosia, L, Vinciguerra, A, Borghetti, P, Trodella, L, Francolini, G, Timon, G, Matrone, F, Ognibene, L, Franzese, C, Jereczek-Fossa, B, Arcangeli, S, Marvaso G., Nicosia L., Vinciguerra A., Borghetti P., Trodella L. E., Francolini G., Timon G., Matrone F., Ognibene L., Franzese C., Jereczek-Fossa B. A., and Arcangeli S.

Abstract

Radiotherapy (RT) is rarely used in the palliative management of muscle-invasive bladder cancer (MIBC). This survey aims to explore current care patterns within the Italian Radiation Oncologist community on this topic. In 2020, the uro-oncological study group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) conducted a survey evaluating the RT role in advanced MIBC. An electronic questionnaire was administered online to the society members asking for: general considerations, patients’ selection, and aim of the treatment, RT schedule and practical consideration, past and future perspective. Sixty-one questionnaires were returned (33% response rate). Most responders (62.30%) declared to work in a Center with a multidisciplinary uro-oncological team, and 8.20% to evaluate more than 20 patients with MIBC/year for palliative RT. Elderly patients were the most frequently evaluated (46.7%) and life expectancy was the most common selection criteria (44.60%). Thirty Gy in 10 fractions (58.9%), whole bladder as GTV (62.5%), PTV isotropic margins of 1.5–2 cm (44.6%) and IMRT/VMAT technique (58.14%) were the most common treatment choices. Patients amenable for bladder palliative RT were most commonly referred by the urologist (43.86%) or the multidisciplinary team (38%). The reported main reasons for the low involvement of radiation oncologist in the management of MIBC patients were low attention to the palliative setting in bladder cancer (37.5%); radiation oncologist not involved in the management of these patients (32.1%); cases not discussed in the multidisciplinary board (26.8%). This survey illustrated the current use of palliative RT for patients with advanced MIBC in Italy and suggested the need for a greater involvement of radiation oncologists in their management.

Published
2021

12. OC-0605 Early outcomes of a randomized trial of SBRT and Abiraterore in mCPRC: ARTO trial NCT03449719

Author

Francolini, G., primary, Detti, B., additional, Di Cataldo, V., additional, Caini, S., additional, Alitto, A.R., additional, Parisi, S., additional, Demofonti, C., additional, Bruni, A., additional, Ingrosso, G., additional, Timon, G., additional, Tagliagambe, A., additional, Aquilano, M., additional, Ciccone, L.P., additional, Salvestrini, V., additional, Frosini, G., additional, Cerbai, C., additional, Allegra, A., additional, Burchini, L., additional, Desideri, I., additional, Mangoni, M., additional, Meattini, I., additional, and Livi, L., additional

Published
2022
Full Text
View/download PDF

17. Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point—a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)

Author

Francolini, G., primary, Timon, G., additional, Matrone, F., additional, Marvaso, G., additional, Nicosia, L., additional, Ognibene, L., additional, Vinciguerra, A., additional, Trodella, L. E., additional, Franzese, C., additional, Borghetti, P., additional, Jereczek-Fossa, B. A., additional, and Arcangeli, S., additional

Published
2021
Full Text
View/download PDF

18. P104 - Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: Freedom from biochemical, radiological progression free survival and freedom from following treatment approaches within a randomized phase II trial (ARTO – NCT03449719)

Author

Francolini, G., Detti, B., Di Cataldo, V., Caini, S., Bruni, A., Ingrosso, G., D’angelillo, R.M., Alitto, A.R., Augugliaro, M., Triggiani, L., Parisi, S., Facchini, G., Banini, M., Simontacchi, G., Desideri, I., Meattini, I., Frosini, G., Burchini, L., Marvaso, G., Alongi, F., Arcidiacono, F., Lancia, A., Genovesi, D., Franzese, C., Timon, G., Tagliagambe, A., and Livi, L.

Published
2023
Full Text
View/download PDF

20. Radiomics Analysis of Stereotactic Body Radiation Therapy Patients with Lung Cancer as a Toxicity Biomarker

Author

Galaverni, M., primary, Chendi, A., additional, Trojani, V., additional, Bertolini, M., additional, Botti, A., additional, Ciammella, P., additional, Ruggieri, M.P., additional, Giaccherini, L., additional, Blandino, G., additional, Manicone, M., additional, Rossi, R., additional, Timon, G., additional, Cozzi, S., additional, Bardoscia, L., additional, Solla, S.D., additional, Orlandi, M., additional, Fioroni, F., additional, Spaggiari, L., additional, Iori, M., additional, and Iotti, C., additional

Published
2020
Full Text
View/download PDF

22. 1369P Biochemical outcomes from ARTO trial (NCT03449719) a phase II randomized trial testing association between abiraterone acetate and stereotactic body radiation therapy in castrate-resistant prostate cancer patients

Author

Francolini, G., Detti, B., Di Cataldo, V., Caini, S., Alitto, A.R., S. Parisi, Demofonti, C., Bruni, A., Ingrosso, G., Timon, G., Allegra, A.G., Burchini, L., Salvestrini, V., Frosini, G., Cerbai, C., Visani, L., Becherini, C., Desideri, I., Meattini, I., and Livi, L.

Published
2022
Full Text
View/download PDF

23. First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study

Author

Masini, C., primary, Ciammella, P., additional, Timon, G., additional, Gnoni, R., additional, De Giorgi, U.F.F., additional, Bellia, S.R., additional, Buti, S., additional, Salaroli, F., additional, Milella, M., additional, Mazzarotto, R., additional, Mucciarini, C., additional, Vitale, M.G., additional, Bruni, A., additional, Procopio, G., additional, Kinspergher, S., additional, Nole, F., additional, Morelli, F., additional, Pappagallo, G., additional, buttigliero, C., additional, and Pinto, C., additional

Published
2019
Full Text
View/download PDF

24. EP-1248 Stereotactic radiotherapy for brain metastasis and systemic therapies: a safe combination?

Author

Manicone, M., primary, Galaverni, M., additional, Renna, I., additional, Ciammella, P., additional, Giaccherini, L., additional, Bellafiore, F., additional, Timon, G., additional, Vigo, F., additional, Rosca, A., additional, Ramundo, D., additional, Galeandro, M., additional, Ruggieri, M.P., additional, Palmieri, T., additional, Botti, A., additional, Sghedoni, R., additional, Cagni, E., additional, Orlandi, M., additional, Russo, M., additional, Bonelli, C., additional, Pagano, M., additional, and Iotti, C., additional

Published
2019
Full Text
View/download PDF

26. EP-1382 Texture analysis of FDG-PET in NSCLC treated with SBRT:a validation study of two prognostic features

Author

Bertolini, M., primary, Galaverni, M., additional, Manicone, M., additional, Renna, I., additional, Ciammella, P., additional, Giaccherini, L., additional, Bellafiore, F., additional, Timon, G., additional, Vigo, F., additional, Rosca, A., additional, Ramundo, D., additional, Galeandro, M., additional, Ruggieri, M.P., additional, Palmieri, T., additional, Botti, A., additional, Orlandi, M., additional, Sghedoni, R., additional, Cagni, E., additional, Grassi, E., additional, Fioroni, F., additional, Filice, A., additional, Casali, M., additional, Iori, M., additional, and Iotti, C., additional

Published
2019
Full Text
View/download PDF

27. EP-1650 Elderly glioblastoma patients:role of multidimensional assessment of frailty in predicting outcomes

Author

Giaccherini, L., primary, Ciammella, P., additional, Galaverni, M., additional, Manicone, M., additional, Renna, I., additional, Galeandro, M., additional, Timon, G., additional, Bellafiore, F., additional, Ramundo, D., additional, Vigo, F., additional, Rosca, A., additional, Palmieri, T., additional, Ruggieri, M.P., additional, Botti, A., additional, Sghedoni, R., additional, Cagni, E., additional, Orlandi, M., additional, Iori, M., additional, Russo, M., additional, and Iotti, C., additional

Published
2019
Full Text
View/download PDF

29. EP-1579: SBRT for limited lymph node recurrence in patients with prostate cancer

Author

Renna, I., primary, Lattanzi, E., additional, Galaverni, M., additional, Timon, G., additional, Vigo, F., additional, Galeandro, M., additional, Rosca, A., additional, Ramundo, D., additional, Ciammella, P., additional, Giaccherini, L., additional, Bellafiore, F., additional, Ruggieri, M.P., additional, Sghedoni, R., additional, Botti, A., additional, Orlandi, M., additional, and Iotti, C., additional

Published
2018
Full Text
View/download PDF

32. EP-1342: Salvage stereotactic body radiotherapy for lymph node oligorecurrent prostate cancer

Author

Fanetti, G., primary, Fodor, C., additional, Ciardo, D., additional, Santoro, L., additional, Francia, C.M., additional, Muto, M., additional, Surgo, A., additional, Zerini, D., additional, Marvaso, G., additional, Timon, G., additional, Romanelli, P., additional, Rondi, E., additional, Comi, S., additional, Cattani, F., additional, Matei, D.V., additional, Ferro, M., additional, Musi, G., additional, Nolè, F., additional, De Cobelli, O., additional, Ost, P., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2017
Full Text
View/download PDF

33. EP-1339: Feasibility and efficacy of moderately hypofractionated radiotherapy in high risk prostate cancer

Author

Marvaso, G., primary, Riva, G., additional, Bassi, C., additional, Fodor, C., additional, Ciardo, D., additional, Zerini, D., additional, Timon, G., additional, Surgo, A., additional, Maucieri, A., additional, Pansini, F., additional, De Marco, P., additional, Cattani, F., additional, De Cobelli, O., additional, Orecchia, R., additional, and Jereczek-Fossa, B., additional

Published
2017
Full Text
View/download PDF

34. EP-1338: High precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion

Author

Riva, G., primary, Timon, G., additional, Ciardo, D., additional, Bazani, A., additional, Maestri, D., additional, De Lorenzo, D., additional, Pansini, F., additional, Cambria, R., additional, Cattani, F., additional, Marvaso, G., additional, Zerini, D., additional, Rojas, D.P., additional, Volpe, S., additional, Golino, F., additional, Scroffi, V., additional, Fodor, C., additional, Petralia, G., additional, De Cobelli, O., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2017
Full Text
View/download PDF

35. 961P - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study

Author

Masini, C., Ciammella, P., Timon, G., Gnoni, R., De Giorgi, U.F.F., Bellia, S.R., Buti, S., Salaroli, F., Milella, M., Mazzarotto, R., Mucciarini, C., Vitale, M.G., Bruni, A., Procopio, G., Kinspergher, S., Nole, F., Morelli, F., Pappagallo, G., buttigliero, C., and Pinto, C.

Published
2019
Full Text
View/download PDF

41. EP-1372: Salvage image-guided stereotactic re-irradiation of local recurrence in prostate cancer

Author

Timon, G., primary, Zerini, D., additional, Fodor, C., additional, Bazzani, F., additional, Maucieri, A., additional, Ronchi, S., additional, Rojas, D.P., additional, Volpe, S., additional, Vavassori, A., additional, Cattani, F., additional, Garibaldi, C., additional, Comi, S., additional, Cambria, R., additional, De Cobelli, O., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2016
Full Text
View/download PDF

42. OC-0448: Give me five: extreme hypofractionated IG-IMRT for organ confined prostate cancer

Author

Jereczek-Fossa, B.A., primary, Ciardo, D., additional, Colangione, S.P., additional, Fodor, C., additional, Zerini, D., additional, Cecconi, A., additional, Surgo, A., additional, Gerardi, M.A., additional, Muto, M., additional, Timon, G., additional, Comi, S., additional, Pansini, F., additional, Bazani, A., additional, Maestri, D., additional, Garioni, M., additional, Scroffi, V., additional, Cattani, F., additional, Cambria, R., additional, De Cobelli, O., additional, and Orecchia, R., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results